TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23398595
Drug: Hormonal treatment
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal treatment alone
Study: 17805061
Drug: Induction carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction carboplatin (AUC = 5.5) on days 1 and 22, vinorelbine (25 mg/m2) on days 1, 8, 22, and 29, followed by intravenous topotecan (0.5 mg/m2) on days 43 to 47, days 57 to 61, and days 71 to 75 with accelerated radiotherapy (RT) at 2 Gy per fraction, twice daily for five consecutive days, every other week, to a cumulative dose of 60 Gy during a 5-week period.
Study: 9065294
Drug: Decontamination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decontamination with polymyxin B (100 mg), tobramycin (80 mg), vancomycin (125 mg), and amphotericin B (500 mg) four times per day orally from the day before the operation until the seventh postoperative day
Study: 2906153
Drug: m-chlorophenyl-piperazine (MCPP)
Normalized name: Piperazine
DrugBank: Piperazine (DB00592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: m-chlorophenyl-piperazine (MCPP) (0.25 mg/kg)
Study: 31206225
Drug: Curcumin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin supplementation (500 mg per day)
Study: 14528504
Drug: lenercept 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: lenercept 0.5 mg/kg (maximum 50 mg)
Study: 15513354
Drug: Anti-H. pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-H. pylori treatment
Study: 11106679
Drug: Beta-carotene treatment
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene treatment
Study: 7472109
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid treatment
Study: 4070320
Drug: bezafibrate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: bezafibrate (200 mg 3-times daily)
Study: 4070320
Drug: clofibrate (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: clofibrate (500 mg 3-times daily)
Study: 29898793
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy for Insomnia (CBT-I)
Study: 18474113
Drug: Cooling treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooling treatment (hand inserted into a rigid chamber with subatmospheric pressure and cooled metal surface at 18-22 degrees C)
Study: 15841739
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose (400/1000)
Study: 15841739
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose (200/500)
Study: 23817989
Drug: Second-generation antipsychotic
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation antipsychotic medications
Study: 10921468
Drug: Loratadine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine (0.3 mg/kg)
Study: 22466551
Drug: LTG monotherapy
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTG monotherapy
Study: 29224648
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral multivitamins and multiminerals (6 tablets daily)
Study: 25440203
Drug: Standard physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard physiotherapy treatment accompanied by 20min knee joint distraction
Study: 22508468
Drug: Oral triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral triple therapy (MTX plus sulfasalazine plus hydroxychloroquine)
Study: 30530121
Drug: No β‐blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: No β‐blocker therapy
Study: 27242368
Drug: Standard azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard azathioprine maintenance therapy (1.5-2.0 mg/kg until 1 year after diagnosis, then tapering to 25 mg every 3 months)
Study: 27242368
Drug: Extended azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Extended azathioprine maintenance therapy
Study: 18420532
Drug: Midazolam (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (8 mg) after 28 days of GBE administration
Study: 15885510
Drug: Standard Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Administration (SA)
Study: 25962611
Drug: Spinal anaesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anaesthesia (SA) using hyperbaric bupivacaine 9 mg with fentanyl 15 µg
Study: 23820501
Drug: OCA regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCA regimen (omeprazole 20mg, clarithromycin 500mg, amoxicillin 1g)
Study: 23820501
Drug: OMAB regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMAB regimen (omeprazole 20mg, metronidazole 500mg, amoxicillin 1g, bismuth subcitrate 240mg)
Study: 24358067
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg twice daily
Study: 12200985
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose EPO (250 IU/kg)
Study: 12200985
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose EPO (400 IU/kg)
Study: 12200985
Drug: Combined low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined low and high dose EPO
Study: 507789
Drug: Amoxicillin alone
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin alone
Study: 2011422
Drug: Amoxicillin with
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin with myringotomy
Study: 30918967
Drug: Dolutegravir (DTG)
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dolutegravir (DTG) 50 mg twice daily during and 2 weeks after tuberculosis therapy, then 50 mg once daily for 52 weeks
Study: 30918967
Drug: Efavirenz (EFV)
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz (EFV) 600 mg daily with 2 nucleoside reverse transcriptase inhibitors for 52 weeks
Study: 29066437
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D 4000 IU (100 μg) daily
Study: 17393618
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no leukogenic drugs)
Study: 15733486
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment with indocyanine green solution (1 mg/ml) injected submucosally and diode laser (power 10 watts) applied to the surface from the esophagogastric junction to 5 cm above it.
Study: 15733486
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without any treatments.
Study: 11555762
Drug: Budesonide aqueous
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide aqueous nasal spray (n = 9)
Study: 26435229
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy administered to 25 patients
Study: 26435229
Drug: No physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: No physical therapy administered to 28 patients
Study: 12007953
Drug: EBRT (50.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBRT (50.4 Gy/28 fractions) with concurrent continuous infusion of 5-FU (200 mg/m²/day)
Study: 12007953
Drug: EBRT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBRT with concurrent continuous 5-FU infusion
Study: 1684678
Drug: Diuretic triampur
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic triampur
Study: 1684678
Drug: Alpha 1-adrenergic
Normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha 1-adrenergic blocker prazosin
Study: 6122752
Drug: Combined beta‐blocker‐chlorthalidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined beta‐blocker‐chlorthalidone treatment
Study: 27185680
Drug: Oral mask
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral mask (OM) ventilation
Study: 16498702
Drug: Reference Pricing
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference Pricing (RP) for anti-hypertensive drugs
Study: 31218477
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D3 (50,000 IU weekly for 12 weeks, followed by 2000 IU daily for 40 weeks)
Study: 11120722
Drug: Oral route
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral route
Study: 20856123
Drug: Fluoxetine 20-40
Normalized name: fluoxetine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20-40 mg/day
Study: 16028252
Drug: Systemic thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic thrombolysis with rtPA and GPIIb/IIIa receptor antagonist tirofiban
Study: 6924538
Drug: Single-dose amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose amoxicillin (3 g)
Study: 15586364
Drug: Ablative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ablative therapy (APC or PDT)
Study: 8120703
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or no drug
Study: 3164762
Drug: Sublingual lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual lorazepam (2 to 3 mg)
Study: 3164762
Drug: Intramuscular diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular diazepam (0.25 mg/kg)
Study: 30291994
Drug: Mean lung
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean lung dose (MLD) with n = 1
Study: 26402075
Drug: Nutraceutical formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutraceutical formulation (NF: folate, alpha‐tocopherol, B12, S‐adenosyl methionine, N‐acetyl cysteine, acetyl‐L‐carnitine)
Study: 26967219
Drug: Nutraceutical formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutraceutical formulation (NF)
Study: 22852832
Drug: Standard Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Care (recommendation for a smoking cessation medication and information about community resources)
Study: 19383060
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of abnormal glycaemia, hypertension, and dyslipidaemia
Study: 17274708
Drug: Test SEI
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test SEI with nanometer-sized calcium phosphate treatment
Study: 15159491
Drug: Minocycline up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline up to 400 mg/day for 8 months (mean tolerated dose 387 mg/day)
Study: 9828914
Drug: PD-GHRH test
Normalized name: Poly Hist PD
DrugBank: Thonzylamine (DB11235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-GHRH test with hydrocortisone (HC) 80 mg/day for 1 day
Study: 2678497
Drug: Metoclopramide (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (15 mg)
Study: 9425968
Drug: Droperidol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol (0.5 mg)
Study: 31901246
Drug: Cinnamon supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamon supplementation (3 grams daily for 8 weeks)
Study: 31238029
Drug: Below the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Below the optimal DO2i threshold of 270 mL/min/m2
Study: 21692282
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine
Study: 23382484
Drug: 50mg sildenafil
Normalized name: sildenafil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg sildenafil (PDE5 inhibitor)
Study: 21281875
Drug: Active grass
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active grass pollen immunotherapy (n = 7)
Study: 11006178
Drug: Micronized 17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized 17 beta‐oestradiol 2 mg and norethisterone acetate 1 mg/day per os
Study: 11006178
Drug: Alendronate 10
Normalized name: ALENDRONATE 10MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 10 mg/day per os
Study: 11006178
Drug: Micronized 17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized 17 beta‐oestradiol 2 mg, norethisterone acetate 1 mg/day per os and alendronate 10 mg/day per os
Study: 2566222
Drug: PUVA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUVA treatment
Study: 12682804
Drug: Cisapride 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 0.2 mg/kg orally every 6 h (group A)
Study: 12682804
Drug: Cisapride 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 0.1 mg/kg orally every 3 h (group B)
Study: 1709600
Drug: Triple drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple drug regimen (rifampicin, isoniazid, pyrazinamide or thiacetazone)
Study: 1709600
Drug: Triple drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple drug regimen (rifampicin, isoniazid)
Study: 1709600
Drug: Single-drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-drug therapy with isoniazid
Study: 25534776
Drug: Neomycin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neomycin (25 mg · kg · day for 4 days/wk) for 6 months
Study: 24338190
Drug: Conventional treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatments (Control)
Study: 19159944
Drug: Enzyme replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme replacement therapy (ERT) with recombinant arylsulfatase B (Naglazyme)
Study: 15308475
Drug: Luteal phase
Normalized name: Nuphar lutea leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteal phase lysine intake (37.7 mg.kg(‐1).day(‐1))
Study: 15308475
Drug: Follicular phase
Normalized name: Follicular hormone
DrugBank: Estrone (DB00655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Follicular phase lysine intake (35.0 mg.kg(‐1).day(‐1))
Study: 9273984
Drug: Social support,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social support, education, or a combination of education and social support
Study: 1093352
Drug: Betamethasone 17-Valerate
Normalized name: Cortisol 17-valerate
DrugBank: Hydrocortisone valerate (DB14544)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone 17-Valerate steroid aerosol
Study: 3293400
Drug: Thiazide diuretic
Normalized name: Thiazide diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide diuretic
Study: 31211805
Drug: Ketoprofen (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (3 mg/kg body weight, intravenous)
Study: 31211805
Drug: Isotonic sterile
Normalized name: Steril-Eyes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic sterile saline solution (control)
Study: 28026901
Drug: Supervised twice‐weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised twice‐weekly resistance exercise training and 150 min/wk of aerobic exercise
Study: 26342247
Drug: Calcium ionophore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium ionophore solution (GM508 Cult‐Active) for 15 minutes after intracytoplasmic sperm injection
Study: 26342247
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no calcium ionophore treatment)
Study: 23433446
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel plus S‐1 (TS)
Study: 22340792
Drug: Insulin local
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin local injection
Study: 16757701
Drug: HPV testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV testing alone at > or = 1 pg/mL
Study: 16757701
Drug: HPV testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV testing alone at > or = 2 pg/mL
Study: 7970014
Drug: Tizanidine (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tizanidine (24 to 36 mg daily in three doses)
Study: 3054651
Drug: Single-dose piperacillin
Normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose piperacillin
Study: 3054651
Drug: Triple-dose cefoxitin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-dose cefoxitin
Study: 21692613
Drug: TPMT genotyping
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPMT genotyping prior to azathioprine treatment
Study: 21692613
Drug: No TPMT
Approvals — FDA: no, EMA: no, PMDA: no
Description: No TPMT genotyping prior to azathioprine treatment
Study: 10227081
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg dexamethasone
Study: 9772611
Drug: Shuizhi-Dahuang mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shuizhi-Dahuang mixture with low dosage of antipsychotic drugs
Study: 9772611
Drug: Antipsychotic drugs
Normalized name: Diazepines, oxazepines, thiazepines and oxepines antipsychotic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic drugs only (control group)
Study: 27814259
Drug: Medical history
Normalized name: histolyn CYL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical history questionnaire with additional item about dietary supplement use (n = 102)
Study: 18692646
Drug: Electrocautery and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrocautery and collagen patches (TachoSil)
Study: 2132185
Drug: Slow release
Normalized name: Slow Release Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow release formulation of bezafibrate (Bezalip Mono)
Study: 7000474
Drug: Cimetidine (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1200 mg daily)
Study: 2979275
Drug: Cimetidine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (800 mg daily)
Study: 340327
Drug: Intensive regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive regimen of Al‐Mg antacid (210 ml daily)
Study: 3551508
Drug: Antacid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid treatment
Study: 30427698
Drug: Six 1-g
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Six 1-g NaCl tablets (salt intervention trial)
Study: 27854539
Drug: CHW-led health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHW-led health literacy intervention with tailored cancer-screening brochure, training, and monthly counseling.
Study: 9649996
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia with morphine-bupivacaine combination (Group A)
Study: 8530314
Drug: Oral amoxicillin
Normalized name: amoxicillin Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin plus clavulanic acid
Study: 8530314
Drug: No perioperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No perioperative antibiotics
Study: 24823464
Drug: Dutasteride (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride (0.5 mg daily; n = 16)
Study: 24823464
Drug: Finasteride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (5 mg daily; n = 16)
Study: 24823464
Drug: Tamsulosin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.4 mg daily; n = 14)
Study: 18634163
Drug: Anakinra 100
Normalized name: ANAKINRA 100MG INJ,SYRINGE,1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra 100 mg once daily for up to 36 weeks
Study: 11148740
Drug: Neoadjuvant and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant and adjuvant alpha-blocker therapy
Study: 2291755
Drug: Pivmecillinam 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivmecillinam 200 mg t.i.d. for 3 days
Study: 2291755
Drug: Pivmecillinam 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivmecillinam 200 mg t.i.d. for 7 days
Study: 6127747
Drug: Diazepam 15
Normalized name: diazepam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 15 mg
Study: 31154681
Drug: Post-immersion rehydration
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-immersion rehydration (RH) with 1 L of water
Study: 28391147
Drug: Pelvic floor
Normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic floor training programme (daily perineal massage and pelvic floor exercises from 32 weeks of pregnancy until birth)
Study: 26371518
Drug: Atorvastatin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin + hydroxychloroquine 200 mg
Study: 23577913
Drug: Web-based training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based training on cognitive behavioral therapy (CBT) skills
Study: 21443446
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment, n=5)
Study: 8141105
Drug: ondansetron 1
Normalized name: ondansetron 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 1 mg three times per day for 3 days
Study: 8141105
Drug: ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 4 mg three times per day for 3 days
Study: 8141105
Drug: ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 8 mg three times per day for 3 days
Study: 8141105
Drug: ondansetron (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron (all doses)
Study: 9422292
Drug: ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 8 mg
Study: 23810271
Drug: 3% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% lidocaine emulsion formulation (NOPAYNE™)